The study aims to investigate the safety and tolerability of the treatment in progressive doses while assessing longer term efficacy measures for the design of future clinical trials with ReN001.
In the study, the company has administered ReN001 in around 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.
The PISCES stusy is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.